Study Suggests Alternative to Common HCV Treatment with Equally High SVR, No PPI Modification Needed

  Mitchell L. Shiffman, MD, FACG Poster 413 Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials Author Insight from Mitchell L Shiffman, MD, FACG, Director, ...

Depression and Chronic Hepatitis C: A Common and Costly Association

Zobair M. Younossi, MD, MPH, FACG Poster 1811 Depression and Chronic Hepatitis C (CH-C): A Common and Costly Association Author Insight from Zobair M. Younossi, MD, MPH FACG, Center for Liver Diseases, Inova Fairfax Hospital What’s new here ...

Successful Treatment of HCV Patients May Hinge on Strategies that Maximize Screening, Provide Links to Appropriate Care

Zobair M. Younossi, MD, MPH, FACG Poster 1815 Implementation of Baby Boomer Hepatitis C (HCV) Screening and Linking to Care in Gastroenterology (GE) Practices: A Multi-Center Pilot Study Author Insight from Zobair M. Younossi, MD, MPH FACG, ...

Study Suggests Eradication of Hepatitis C after Curative Therapy Can Reduce Cancer Recurrence, Increase Survival

  Swathi Paleti, MD Prashant Pandya, MD Sashidhar Manthravadi, MD Oral 2 Prognostic Impact of Achieving SVR in Patients With Hepatitis C After Curative Treatment of HCC: A Systematic Review and Meta-analysis. Author Insight from Sashidhar Manthravadi, ...

Study Suggests All-Oral Therapy for HCV G1 Patients is Highly Effective, Regardless of Race or Ethnicity

Nancy Reau, MD Oral 65 High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/R+dasabuvir+/-Ribavirin: Integrated Safety and Efficacy Analysis Author ...

Study: Arthritis Risk More than Double in People with Hepatitis C, with Costs to Treat HCV-Related Arthritis $11.0 million per Year

Zobair M. Younossi, MD, MPH, FACG Poster 1810 Hepatitis C Virus (HCV) Related Arthritis and Arthralgia: The Epidemiologic and Economic Burden in the United States Author Insight from Zobair M. Younossi, MD, MPH FACG, Center for Liver Diseases, ...